IMPACT OF CONDITIONING INTENSITY OF ALLOGENEIC TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH GENOMIC EVIDENCE OF RESIDUAL DISEASE

A PHASE 3 STUDY OF VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE

THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS

ASCEND PHASE 3 STUDY OF ACALABRUTINIB VS INVESTIGATOR’S CHOICE OF RITUXIMAB PLUS IDELALISIB (IDR) OR BENDAMUSTINE (BR) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

DASFREE 2-YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR)

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL - ANALYSIS FROM THE TOURMALINE-MM3 STUDY

RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

RESULTS FROM THE FIRST-IN-HUMAN STUDY OF MIVEBRESIB (ABBV-075), A PAN-INHIBITOR OF BROMODOMAIN AND EXTRA TERMINAL PROTEINS, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP-FRACTIONATED DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL)

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY